Trade Qiagen NV - QIA CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.130 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.022102% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.000121% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 0.001 | ||||||||
Currency | EUR | ||||||||
Margin | 5% | ||||||||
Stock exchange | Germany | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Qiagen NV ESG Risk Ratings
‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly
Prev. Close* | 36.95 |
Open* | 36.745 |
1-Year Change* | -12.64% |
Day's Range* | 36.64 - 36.985 |
52 wk Range | 34.74-50.82 |
Average Volume (10 days) | 1.80M |
Average Volume (3 months) | 27.32M |
Market Cap | 10.19B |
P/E Ratio | 30.96 |
Shares Outstanding | 228.18M |
Revenue | 1.95B |
EPS | 1.44 |
Dividend (Yield %) | N/A |
Beta | 0.43 |
Next Earnings Date | Feb 6, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 18, 2024 | 36.980 | 0.110 | 0.30% | 36.870 | 37.025 | 36.490 |
Apr 17, 2024 | 36.950 | 0.245 | 0.67% | 36.705 | 37.095 | 36.685 |
Apr 16, 2024 | 36.925 | -0.035 | -0.09% | 36.960 | 37.270 | 36.765 |
Apr 15, 2024 | 37.460 | -0.365 | -0.96% | 37.825 | 37.975 | 37.395 |
Apr 12, 2024 | 38.080 | -0.295 | -0.77% | 38.375 | 38.470 | 38.005 |
Apr 11, 2024 | 38.165 | -0.115 | -0.30% | 38.280 | 38.745 | 38.140 |
Apr 10, 2024 | 38.445 | 0.160 | 0.42% | 38.285 | 38.600 | 38.070 |
Apr 9, 2024 | 38.170 | 0.195 | 0.51% | 37.975 | 38.305 | 37.865 |
Apr 8, 2024 | 37.980 | 0.135 | 0.36% | 37.845 | 38.140 | 37.750 |
Apr 5, 2024 | 37.740 | -0.030 | -0.08% | 37.770 | 37.945 | 37.580 |
Apr 4, 2024 | 38.110 | -0.330 | -0.86% | 38.440 | 38.635 | 38.005 |
Apr 3, 2024 | 38.595 | -0.565 | -1.44% | 39.160 | 39.260 | 38.140 |
Apr 2, 2024 | 39.335 | -0.115 | -0.29% | 39.450 | 39.700 | 39.035 |
Mar 28, 2024 | 39.620 | 0.295 | 0.75% | 39.325 | 39.685 | 39.115 |
Mar 27, 2024 | 39.230 | 0.510 | 1.32% | 38.720 | 39.595 | 38.720 |
Mar 26, 2024 | 39.025 | -0.400 | -1.01% | 39.425 | 39.720 | 38.700 |
Mar 25, 2024 | 39.840 | -0.360 | -0.90% | 40.200 | 40.315 | 39.750 |
Mar 22, 2024 | 39.905 | -0.340 | -0.84% | 40.245 | 40.430 | 39.895 |
Mar 21, 2024 | 40.450 | 0.605 | 1.52% | 39.845 | 40.500 | 39.845 |
Mar 20, 2024 | 40.210 | -0.385 | -0.95% | 40.595 | 40.595 | 40.145 |
Qiagen NV Events
Time (UTC) | Country | Event |
---|---|---|
Monday, April 29, 2024 | ||
Time (UTC) 20:00 | Country NL
| Event Q1 2024 Qiagen NV Earnings Release Q1 2024 Qiagen NV Earnings ReleaseForecast -Previous - |
Tuesday, April 30, 2024 | ||
Time (UTC) 13:00 | Country NL
| Event Q1 2024 Qiagen NV Earnings Call Q1 2024 Qiagen NV Earnings CallForecast -Previous - |
Friday, June 21, 2024 | ||
Time (UTC) 08:00 | Country NL
| Event Qiagen NV Annual Shareholders Meeting Qiagen NV Annual Shareholders MeetingForecast -Previous - |
Tuesday, August 6, 2024 | ||
Time (UTC) 20:05 | Country NL
| Event Q2 2024 Qiagen NV Earnings Release Q2 2024 Qiagen NV Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 2141.52 | 2251.66 | 1870.35 | 1526.42 | 1501.85 |
Revenue | 2141.52 | 2251.66 | 1870.35 | 1526.42 | 1501.85 |
Cost of Revenue, Total | 756.955 | 800.837 | 637.631 | 521.162 | 499.271 |
Gross Profit | 1384.56 | 1450.82 | 1232.71 | 1005.26 | 1002.58 |
Total Operating Expense | 1610.06 | 1621.57 | 1483.92 | 1547.76 | 1235.27 |
Selling/General/Admin. Expenses, Total | 603.945 | 584.468 | 525.362 | 505.268 | 508.146 |
Research & Development | 189.859 | 189.964 | 149.072 | 157.448 | 161.852 |
Depreciation / Amortization | 14.531 | 18.542 | 20.811 | 29.973 | 39.032 |
Unusual Expense (Income) | 44.768 | 27.762 | 151.039 | 333.91 | 26.966 |
Operating Income | 531.46 | 630.084 | 386.431 | -21.337 | 266.581 |
Interest Income (Expense), Net Non-Operating | -19.1 | -5.122 | -59.918 | -43.696 | -70.168 |
Other, Net | 0.241 | 0.871 | 112.959 | -12.743 | 29.324 |
Net Income Before Taxes | 512.601 | 625.833 | 439.472 | -77.776 | 225.737 |
Net Income After Taxes | 423.211 | 512.599 | 359.188 | -41.455 | 190.38 |
Minority Interest | 0 | ||||
Net Income Before Extra. Items | 423.211 | 512.599 | 359.188 | -41.455 | 190.38 |
Net Income | 423.211 | 512.599 | 359.188 | -41.455 | 190.38 |
Income Available to Common Excl. Extra. Items | 423.211 | 512.599 | 359.188 | -41.455 | 190.38 |
Income Available to Common Incl. Extra. Items | 423.211 | 512.599 | 359.188 | -41.455 | 190.38 |
Dilution Adjustment | 0 | ||||
Diluted Net Income | 423.211 | 512.599 | 359.188 | -41.455 | 190.38 |
Diluted Weighted Average Shares | 230.136 | 232.034 | 234.214 | 226.777 | 233.456 |
Diluted EPS Excluding Extraordinary Items | 1.83896 | 2.20915 | 1.53359 | -0.1828 | 0.81549 |
Diluted Normalized EPS | 1.99957 | 2.30715 | 2.00343 | 0.77427 | 0.9129 |
Total Extraordinary Items |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 494.857 | 485.398 | 497.984 | 499.631 | 515.512 |
Revenue | 494.857 | 485.398 | 497.984 | 499.631 | 515.512 |
Cost of Revenue, Total | 182.705 | 177.922 | 180.46 | 178.58 | 184.494 |
Gross Profit | 312.152 | 307.476 | 317.524 | 321.051 | 331.018 |
Total Operating Expense | 389.425 | 388.688 | 393.411 | 401.972 | 393.355 |
Selling/General/Admin. Expenses, Total | 145.523 | 147.58 | 154.211 | 145.462 | 151.418 |
Research & Development | 49.893 | 54.718 | 44.719 | 48.868 | 49.896 |
Depreciation / Amortization | 2.702 | 2.657 | 5.969 | 2.846 | 2.799 |
Unusual Expense (Income) | 8.602 | 5.811 | 8.052 | 26.216 | 4.748 |
Operating Income | 105.432 | 96.71 | 104.573 | 97.659 | 122.157 |
Interest Income (Expense), Net Non-Operating | -3.054 | 11.954 | 1.387 | -2.452 | -6.521 |
Other, Net | -0.062 | 0.123 | -0.123 | 0.511 | -0.112 |
Net Income Before Taxes | 102.316 | 108.787 | 105.837 | 95.718 | 115.524 |
Net Income After Taxes | 80.786 | 85.035 | 88.844 | 82.394 | 96.661 |
Net Income Before Extra. Items | 80.786 | 85.035 | 88.844 | 82.394 | 96.661 |
Net Income | 80.786 | 85.035 | 88.844 | 82.394 | 96.661 |
Income Available to Common Excl. Extra. Items | 80.786 | 85.035 | 88.844 | 82.394 | 96.661 |
Income Available to Common Incl. Extra. Items | 80.786 | 85.035 | 88.844 | 82.394 | 96.661 |
Diluted Net Income | 80.786 | 85.035 | 88.844 | 82.394 | 96.661 |
Diluted Weighted Average Shares | 230.517 | 230.602 | 230.358 | 230.084 | 229.938 |
Diluted EPS Excluding Extraordinary Items | 0.35046 | 0.36875 | 0.38568 | 0.3581 | 0.42038 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | 0.37992 | 0.38845 | 0.41502 | 0.45618 | 0.43766 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 2393.95 | 2109.6 | 1624.41 | 1570.25 | 2155.06 |
Cash and Short Term Investments | 1418.27 | 1065.3 | 715.233 | 753.233 | 1393.69 |
Cash | 122.314 | 235.381 | 245.373 | 189.569 | 208.083 |
Short Term Investments | 687.597 | 184.785 | 117.249 | 563.664 | 1185.6 |
Total Receivables, Net | 434.068 | 469.663 | 486.605 | 484.608 | 422.091 |
Accounts Receivable - Trade, Net | 333.518 | 376.213 | 389.058 | 385.117 | 351.612 |
Total Inventory | 357.96 | 327.525 | 291.181 | 170.704 | 162.912 |
Prepaid Expenses | 50.958 | 60.629 | 61.159 | 45.409 | 48.25 |
Other Current Assets, Total | 132.7 | 186.484 | 70.227 | 116.294 | 128.122 |
Total Assets | 6287.73 | 6146.95 | 5869.62 | 5235.62 | 5748.33 |
Property/Plant/Equipment, Total - Net | 757.693 | 739.077 | 661.894 | 455.243 | 511.659 |
Property/Plant/Equipment, Total - Gross | 1260.66 | 1371.49 | 1292.34 | 1154.37 | 1115.09 |
Accumulated Depreciation, Total | -502.967 | -632.416 | -630.443 | -699.13 | -603.43 |
Goodwill, Net | 2352.57 | 2350.76 | 2364.03 | 2140.5 | 2108.54 |
Intangibles, Net | 544.796 | 627.436 | 726.194 | 632.434 | 475.043 |
Other Long Term Assets, Total | 215.225 | 294.676 | 488.995 | 356.488 | 437.434 |
Total Current Liabilities | 974.523 | 1517.47 | 572.175 | 951.345 | 972.189 |
Accounts Payable | 98.734 | 101.224 | 118.153 | 84.767 | 69.415 |
Accrued Expenses | 215.702 | 219.936 | 220.755 | 332.151 | 209.748 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 389.552 | 847.626 | 42.539 | 285.244 | 503.177 |
Other Current Liabilities, Total | 270.535 | 348.684 | 190.728 | 249.183 | 189.849 |
Total Liabilities | 2821.12 | 3050.4 | 3071.78 | 2699.02 | 3113.36 |
Total Long Term Debt | 1471.9 | 1094.14 | 1880.21 | 1421.11 | 1671.09 |
Long Term Debt | 1471.9 | 1094.14 | 1880.21 | 1421.11 | 1671.09 |
Deferred Income Tax | 17.5 | 37.591 | 39.216 | 23.442 | 63.411 |
Minority Interest | |||||
Other Liabilities, Total | 357.203 | 401.199 | 580.179 | 303.13 | 406.672 |
Total Equity | 3466.61 | 3096.55 | 2797.84 | 2536.59 | 2634.97 |
Common Stock | 2.702 | 2.702 | 2.702 | 2.702 | 2.702 |
Additional Paid-In Capital | 1868.02 | 1818.51 | 1834.17 | 1777.02 | 1742.19 |
Retained Earnings (Accumulated Deficit) | 2160.17 | 1791.74 | 1323.09 | 1178.46 | 1379.62 |
Treasury Stock - Common | -160.188 | -189.73 | -118.301 | -111.966 | -178.903 |
Unrealized Gain (Loss) | 0 | ||||
Other Equity, Total | -404.091 | -326.67 | -243.822 | -309.619 | -310.644 |
Total Liabilities & Shareholders’ Equity | 6287.73 | 6146.95 | 5869.62 | 5235.62 | 5748.33 |
Total Common Shares Outstanding | 227.716 | 227.074 | 227.985 | 227.752 | 225.509 |
Long Term Investments | 23.5 | 25.4 | 4.1 | 80.7 | 60.6 |
Note Receivable - Long Term | |||||
Cash & Equivalents | 608.355 | 645.135 | 352.611 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 1962.39 | 2311.43 | 2251.32 | 2393.95 | 2755.51 |
Cash and Short Term Investments | 1015.78 | 1331.9 | 1287.34 | 1418.27 | 1886.98 |
Cash & Equivalents | 579.935 | 609.549 | 359.18 | 730.669 | 1271.6 |
Short Term Investments | 435.843 | 722.352 | 928.161 | 687.597 | 615.387 |
Total Receivables, Net | 326.69 | 327.899 | 329.544 | 333.518 | 323.175 |
Accounts Receivable - Trade, Net | 326.69 | 327.899 | 329.544 | 333.518 | 323.175 |
Total Inventory | 399.207 | 391.989 | 380.824 | 357.96 | 323.472 |
Prepaid Expenses | 220.715 | 259.639 | 253.609 | 284.208 | 221.882 |
Total Assets | 5906.7 | 6347.27 | 6278.95 | 6287.73 | 6516.62 |
Property/Plant/Equipment, Total - Net | 706.02 | 706.84 | 691.055 | 662.17 | 590.983 |
Property/Plant/Equipment, Total - Gross | 1252.48 | 1222.98 | 1165.14 | 1075.87 | |
Accumulated Depreciation, Total | -545.641 | -531.924 | -502.967 | -484.887 | |
Goodwill, Net | 2434.47 | 2456.54 | 2454.08 | 2352.57 | 2299.26 |
Intangibles, Net | 542.604 | 570.192 | 585.021 | 544.796 | 551.587 |
Long Term Investments | 27.3 | 27.7 | 23.5 | 21 | |
Other Long Term Assets, Total | 261.217 | 274.97 | 269.778 | 310.748 | 298.273 |
Total Current Liabilities | 524.371 | 978.45 | 890.244 | 974.523 | 1497.54 |
Accounts Payable | 76.887 | 83.939 | 84.386 | 98.734 | 82.836 |
Accrued Expenses | 346.876 | 325.962 | 341.615 | 417.237 | 487.562 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | |
Current Port. of LT Debt/Capital Leases | 100.608 | 500.149 | 393.243 | 389.552 | 866.04 |
Other Current Liabilities, Total | 68.4 | 71 | 69 | 61.1 | |
Total Liabilities | 2213 | 2723.66 | 2717.78 | 2821.12 | 3188.86 |
Total Long Term Debt | 1382.36 | 1387.94 | 1486.71 | 1471.9 | 1423.21 |
Long Term Debt | 1382.36 | 1387.94 | 1486.71 | 1471.9 | 1423.21 |
Deferred Income Tax | 17.5 | 9.387 | |||
Other Liabilities, Total | 306.268 | 357.273 | 340.827 | 357.203 | 258.726 |
Total Equity | 3693.7 | 3623.61 | 3561.18 | 3466.61 | 3327.76 |
Common Stock | 2.702 | 2.702 | 2.702 | 2.702 | 2.702 |
Additional Paid-In Capital | 1903.08 | 1890.02 | 1882.16 | 1868.02 | 1854.36 |
Retained Earnings (Accumulated Deficit) | 2360.88 | 2283.06 | 2215.43 | 2160.17 | 2072.57 |
Treasury Stock - Common | -134.277 | -134.277 | -142.855 | -160.188 | -160.943 |
Other Equity, Total | -438.687 | -417.902 | -396.261 | -404.091 | -440.933 |
Total Liabilities & Shareholders’ Equity | 5906.7 | 6347.27 | 6278.95 | 6287.73 | 6516.62 |
Total Common Shares Outstanding | 228.182 | 228.182 | 228.035 | 227.716 | 227.7 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 423.211 | 512.599 | 359.188 | -41.455 | 190.38 |
Cash From Operating Activities | 715.264 | 639.001 | 457.806 | 330.843 | 359.496 |
Cash From Operating Activities | 208.397 | 214.931 | 205.014 | 231.458 | 206.436 |
Deferred Taxes | -9.603 | -5.288 | -6.706 | -55.362 | -23.272 |
Non-Cash Items | 125.14 | 46.771 | -27.423 | 240.526 | 81.111 |
Cash Taxes Paid | 98.565 | 102.083 | 42.572 | 41.474 | 29.317 |
Cash Interest Paid | 23.208 | 21.588 | 25.351 | 29.721 | 25.902 |
Changes in Working Capital | -31.881 | -130.012 | -72.267 | -44.324 | -95.159 |
Cash From Investing Activities | -726.763 | -202.426 | -443.281 | -222.278 | -211.356 |
Capital Expenditures | -149.336 | -206.534 | -304.237 | -274.884 | -150.763 |
Other Investing Cash Flow Items, Total | -577.427 | 4.108 | -139.044 | 52.606 | -60.593 |
Cash From Financing Activities | -125.803 | -150.366 | -50.127 | -639.08 | 360.408 |
Financing Cash Flow Items | -17.373 | -16.953 | -23.451 | -61.279 | -8.019 |
Issuance (Retirement) of Stock, Net | 0.121 | -92.068 | 8.876 | 62.362 | -27.867 |
Issuance (Retirement) of Debt, Net | -108.551 | -41.345 | -35.552 | -640.163 | 396.294 |
Foreign Exchange Effects | -12.545 | -3.677 | 4.196 | 0.826 | -7.183 |
Net Change in Cash | -149.847 | 282.532 | -31.406 | -529.689 | 501.365 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 85.035 | 423.211 | 334.367 | 251.973 | 155.312 |
Cash From Operating Activities | 71.926 | 715.264 | 590.945 | 379.363 | 207.41 |
Cash From Operating Activities | 52.061 | 208.397 | 153.725 | 103.408 | 52.998 |
Deferred Taxes | -4.341 | -9.603 | -40.196 | -3.95 | 0.615 |
Non-Cash Items | 13.323 | 125.14 | 95.413 | 47.519 | 21.86 |
Changes in Working Capital | -74.152 | -31.881 | 47.636 | -19.587 | -23.375 |
Cash From Investing Activities | -433.847 | -726.763 | -602.237 | -557.789 | -306.252 |
Capital Expenditures | -38.409 | -149.336 | -102.745 | -76.024 | -38.415 |
Other Investing Cash Flow Items, Total | -395.438 | -577.427 | -499.492 | -481.765 | -267.837 |
Cash From Financing Activities | -9.828 | -125.803 | 420.57 | 12.549 | -10.658 |
Financing Cash Flow Items | -9.903 | -17.373 | 49.011 | 12.443 | -10.687 |
Issuance (Retirement) of Stock, Net | 0.075 | 0.121 | 0.107 | 0.106 | 0.029 |
Issuance (Retirement) of Debt, Net | -108.551 | 371.452 | 0 | 0 | |
Foreign Exchange Effects | 0.26 | -12.545 | -18.197 | -8.105 | -0.501 |
Net Change in Cash | -371.489 | -149.847 | 391.081 | -173.982 | -110.001 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Qiagen Company profile
About Qiagen NV
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Qiagen NV revenues increased 20% to $2.25B. Net income increased 43% to $512.6M. Revenues reflect Consumables and Related Revenues segment increase of 23% to $1.99B, Instrumentation segment increase of 4% to $265.3M, United States segment increase of 25% to $909.7M, Europe & Middle East & Afric segment increase of 19% to $814.4M. Net income benefited from Restructuring decrease of 81% to $27.8M (expense).
Equity composition
1/2017, Shares Consolidation (Factor: 0.96296).
Industry: | Biotechnology & Medical Research (NEC) |
Hulsterweg 82
VENLO
LIMBURG 5912 PL
NL
Income Statement
- Annual
- Quarterly
News
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com